about
Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.Melanoma Expressed-CD70 Is Regulated by RhoA and MAPK Pathways without Affecting Vemurafenib Treatment Activity.CD70 expression patterns in renal cell carcinoma.Camelid Ig V genes reveal significant human homology not seen in therapeutic target genes, providing for a powerful therapeutic antibody platform.Interaction of tumor cells with infiltrating lymphocytes via CD70 and CD27 in clear cell renal cell carcinoma.Melanoma-expressed CD70 is involved in invasion and metastasis.TNF superfamily: costimulation and clinical applicationsMarine Antibody-Drug Conjugates: Design Strategies and Research Progress.Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy.ATVB Distinguished Scientist Award: How Costimulatory and Coinhibitory Pathways Shape Atherosclerosis.Tyrosine kinase inhibitor-induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling.First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70.CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants.Expression of CD70 in nasal natural killer/T cell lymphoma cell lines and patients; its role for cell proliferation through binding to soluble CD27.Blocking CD27-CD70 costimulatory pathway suppresses experimental colitis.Increased CD70 expression is associated with clinical resistance to cisplatin-based chemotherapy and poor survival in advanced ovarian carcinomas.CD70: A Potential Target in Breast Cancer?CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemiaHypoxia-inducible factor-2 alpha up-regulates CD70 under hypoxia and enhances anchorage-independent growth and aggressiveness in cancer cells.
P2860
Q33417191-60D1703C-DFD5-4889-8AAE-919384E207AEQ35909427-8F955C00-B2E9-4325-9EC1-945A6A32BE83Q36028302-77EDEBCD-203E-46BF-A97E-AFD36FE6EC14Q36214456-E25748EC-F4A9-4DC6-8473-134ABEFEEB73Q36255816-701CCFE2-3924-4B89-AF61-80FACBF4E680Q36472971-E815A572-F43C-44E0-B8A1-AE2F3822834FQ37266849-EA093C0C-BF33-403E-8F3E-AB22CE9E5ABFQ37628646-33965349-4BF7-43F6-85BA-6D8A775C6228Q38120535-289959EB-5ECE-4CB6-B3A9-0DE5BB0059A3Q38737500-43F86960-F2F3-4838-AEBE-0AB4279EAD13Q38848102-3A11E815-DD9D-4804-A7E6-EE644FFA6C20Q38941987-869F4565-1251-4970-86E4-8C116F5BF093Q39028796-41C0BEE3-59CF-4BF1-8AD4-89E140B01748Q39233648-1C096F67-3103-4CC5-8972-6FC6C5D07EC4Q42010165-C6C8CEF5-47B9-4476-8BD6-804383CCA642Q42153370-F3B53D81-FE6C-4E28-AD90-B4A00C56D9F9Q42255651-3D31BA89-28C7-418D-93BA-1F4EF081436BQ42323497-9F827249-AB59-4A90-8795-2F988ACBF1D3Q55006840-980638C7-5AA5-4963-8934-65594BCB822B
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
CD70 as a therapeutic target in human malignancies.
@en
CD70 as a therapeutic target in human malignancies.
@nl
type
label
CD70 as a therapeutic target in human malignancies.
@en
CD70 as a therapeutic target in human malignancies.
@nl
prefLabel
CD70 as a therapeutic target in human malignancies.
@en
CD70 as a therapeutic target in human malignancies.
@nl
P2860
P1476
CD70 as a therapeutic target in human malignancies.
@en
P2093
Iqbal S Grewal
P2860
P304
P356
10.1517/14728222.12.3.341
P407
P577
2008-03-01T00:00:00Z